Personalized medicine for non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

被引：0
|
作者：
Hamada, Akinobu
Sasaki, Ji-ichiro
Saeki, Sho
Iwamoto, Norihiro
Inaba, Megumi
Ushijima, Sunao
Urata, Maki
Kishi, Hiroto
Fujii, Shinji
Semba, Hiroshi
Kai, Yuki
Saito, Hideyuki
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3588
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of brain metastasis from non-small cell lung cancer
    Zhang, Lan-jun
    Cai, Ling
    Zhu, Jian-fei
    Rong, Tie-hua
    Wu, Shao-xiong
    Chen, Zhong-pin
    Liu, Meng-zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] ACTIVATION OF CYTOMEGALOVIRUS IN A PATIENT ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR TREATMENT IN NON-SMALL CELL LUNG CANCER
    Dawes, Sean M.
    Plichta, Christine
    Gaddipati, Himaja
    Hamade, Sam
    Biedny, Adam
    de Villate, Oscar F. Parodi Ortiz
    CHEST, 2023, 164 (04) : 972A - 973A
  • [23] Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
    Zheng, Yuyan
    Zhou, Min
    Arulananda, Surein
    Um, Sang-Won
    Li, Hecheng
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 159 - 164
  • [24] Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer
    Kurihara, Eisuke
    Shien, Kazuhiko
    Torigoe, Hidejiro
    Takeda, Tatsuaki
    Takahashi, Yuta
    Ogoshi, Yusuke
    Yoshioka, Takahiro
    Namba, Kei
    Sato, Hiroki
    Suzawa, Ken
    Yamamoto, Hiromasa
    Soh, Junichi
    Okazaki, Mikio
    Shien, Tadahiko
    Tomida, Shuta
    Toyooka, Shinichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 1767 - 1775
  • [25] Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy
    Sari, Murat
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (01) : 132 - 138
  • [26] Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
    Hasegawa, Takaaki
    Sawa, Toshiyuki
    Futamura, Yohei
    Horiba, Akane
    Ishiguro, Takashi
    Marui, Tsutomu
    Yoshida, Tsutomu
    INTERNAL MEDICINE, 2015, 54 (16) : 1977 - 1980
  • [27] Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
    Tartarone, Alfredo
    Lerose, Rosa
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 242 - 250
  • [28] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
    Kris, MG
    Natale, RB
    Herbst, RS
    Lynch, TJ
    Prager, D
    Belani, CP
    Schiller, JH
    Kelly, K
    Spiridonidis, H
    Sandler, A
    Albain, KS
    Cella, D
    Wolf, MK
    Averbuch, SD
    Ochs, JJ
    Kay, AC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158
  • [29] Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Chung, Doo Hyun
    Heo, Dae Seog
    CANCER RESEARCH AND TREATMENT, 2014, 46 (04): : 323 - 330
  • [30] Characterization of skin pathology in non-small cell lung cancer patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Krueger, James G.
    McCarthy, Sean P.
    Conlan, Maureen G.
    Iwata, Kenneth K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB33 - AB33
12345